TO THE EDITOR
Hematopoietic growth factors (HGF), particularly G-CSF, are widely used in hematopoietic malignancies to reduce the duration of neutropenia induced by chemotherapy and its subsequent infectious complications. In acute myeloid leukemia (AML), G-CSF or GM-CSF has been used to reduce the duration of neutropenia after induction or consolidation therapy. The benefit of such strategies remains controversial: most studies report a shorter duration of neutropenia with a lower incidence of infections in the HGF arms, but no evidence of reduced mortality. 1 When HGF is administered concomitantly with chemotherapy, it recycles leukemic cells and may increase their chemosensitivity. In some studies, patients treated with G-CSF or GM-CSF showed a statistically higher rate of complete remission with improvement of DFS but not overall survival.
1,2 These studies demonstrate that G-CSF or GM-CSF may have an anti-leukemic effect. In fact, leukemic cells display HGF receptors and some authors have shown G-CSF-induced apoptosis of leukemic cell. 3 Comorbid affections due to advanced age or life-threatening infections associated with leukemia can sometimes postpone chemotherapy. Hematopoietic growth factors may be used to temporarily increase the polymorphonuclear neutrophil (PMN) after treatment with G-CSF alone without chemotherapy. 4 In all cases patients had concomitant infections except one case reported by Ferrara et al. 5 We report on three AML patients without infections who entered CR after initial treatment with G-CSF alone. Cytogenetic remission was documented in one case.
Case 1: A 68-year-old woman was admitted for pancytopenia in March 2000. She presented with ulceronecrotic pharyngitis and fever. Physical examination was normal. Blood count on diagnosis showed: WBC 0.5 × 10 9 /l (PMN: 10%, lymphocytes: 90%), no circulating blast cells, Hb 3.5 g/dl, platelets 62 × 10 9 /l. Bone marrow examination revealed hypocellular marrow with 30% of blast cells, expressing MPO and CD33, CD13, CD34 antigens. Acute myeloid leukemia (AML-M2) was diagnosed. Karyotype revealed 46XX del 7q11, del 13q in 14 mitoses and a normal pattern in 12 mitoses. Due to severe neutropenia associated with marrow hypoplasia without blastic proliferation, it was decided to treat with G-CSF alone. Lenograstime rhuG-CSF 263 g (Granocyte 34; Chugai Pharma, France) was administered subcutaneously daily. Two weeks later, WBC increased to 1.6 × 10 9 /l with 60% PMN, Hb 10 g/dl, no circulating blast cells, platelets 90 × 10 9 /l. G-CSF was continued at a dose of 105 g (Granocyte 13) three times a week. Six weeks after starting therapy, blood count showed: 9.3 × 10 9 /l (PMN: 90%, lymphocytes: 10%), Hb 10 g/dl, platelets 261 × 10 9 /l, and no circulating blast cells. Bone marrow examination was normocellular with less than 5% blast cells. The cytogenetic analysis was normalized with disappearance of the abnormal clone. The patient had achieved complete remission with G-CSF alone and died from relapse.
Case 2: A 75-year-old woman presented with neutropenia in April 2000. A routine blood count showed: WBC 2.5 × 10 9 /l (PMN: 15%, lymphocytes: 80%) without circulating blast cells, Hb 11.7 g/dl, plate- Hematological values are indicated on diagnosis (before starting G-CSF) and after 3 months of G-CSF alone. a Deaths occurred due to progression 9 and 6 months after diagnosis in cases 1 and 2, respectively. Patient 3 is alive and in CR 9 months after starting G-CSF.
lets 276 × 10 9 /l. Three years earlier WBC count was normal. There was no history of recurrent infection. Physical examination was normal. Bone marrow smears were hypocellular and showed 40% blast cells (FAB subtype AML-M2) and immunophenotyping analysis showed coexpression of CD13, CD33, CD117 on CD34 leukemic cells (Figure 1a, b, c, d ). Lenograstime rhuG-CSF, (Granocyte 34; Chugai-Aventis) was administered at a daily dose of 263 g/day. One month later, blood count showed: WBC 16.1 × 10 9 /l (PMN: 55%, lymphocytes: 40%), Hb 10 g/dl, and platelets 214 × 10 9 /l. Three months later, the patient entered complete remission. Blood count was normal with no blast cells on marrow examination (Figure 1e ). Despite maintenance therapy with G-CSF, the patient relapsed 6 months later with 74% blast cells on bone marrow smears. Karyotype at relapse detected nine abnormal metaphases (del 7q22) out of 20 metaphases.
Case 3: A 75-year-old woman was admitted for pancytopenia in February 2001. Blood count showed: WBC 1.4 × 10 9 /l (PMN 20%, lymphocytes 80%), no peripheral blast cells, Hb 9.6 g/dl, platelets 90 × 10 9 /l. Bone marrow smears were hypocellular and showed 25% blast cells. MPO, CD13, CD33 antigens were positive with myelodysplastic features. Cytogenetic analysis showed 46 XX. The diagnosis was consistent with AML-M2 (FAB). Lenograstime rhuG-CSF was started at 263 g/day alone and the patient entered complete remission 3 months later with the following blood count: WBC 4.6 × 10 9 /l (PMN 60%), Hb 10 g/l, platelets 151 × 10 9 /l and marrow smears showed no excess of blast cells. Nine months later, the patient is still in remission and G-CSF is administered three times a week at 5 g/kg. The clinico-biological characteristics of the three patients are summarized in Table 1 .
We report on three AML patients who entered CR after G-CSF alone. In the first case, we were able to document cytogenetic remission which lasted over 9 months. Remission lasted 6 months in the second case, and is still observed 9 months later in the third case. G-CSF as a single agent therapy has already proved successful in AML. Fourteen AML cases have been reported, in which complete remission was associated with concomitant infection. 4, 6 It has been suggested that the cytokines produced by concomitant infection could facilitate achievement of CR. Interestingly, our three AML-M2 patients entered CR without concomitant infections. Why these patients responded to G-CSF is unclear. Successful outcome after G-CSF is reported in AML cases with hypoplastic marrow or a relatively low percentage of leukemic cells as observed in myelodysplastic syndrome. It has been suggested that in hypoplastic acute leukemia, leukemic cells must have characteristics that sensitize them to G-CSF. 4 Hypoplastic leukemia appears to proliferate slowly and be characterized by a maturation failure. These conditions could explain the safe use of G-CSF and its efficacy in leukemic cell maturation. The benefit of G-CSF may be due to other biological characteristics. Ferrara et al 5 reported a patient with t(8;21) AML entering complete remission after G-CSF alone, whereas no evidence of infection was seen on diagnosis or during therapy. The duration of remission was short, just 3 months. In AML-M2 with t(8,21) the chimeric protein ETO-AML1 blocks the transcription and differentiation mediated by G-CSF. It has been shown that G-CSF can induce in vitro and in vivo differentiation of AML M2 t(8;21) and degradation of the AML1-ETO oncoprotein. 7 G-CSF could also suppress the leukemic cell clone by inducing apoptosis and suppress the renewal of leukemic cells. Another possible explanation for the antileukemic effect of G-CSF is a potential increase in effector cytotoxic cells secondary to increased normal hematopoiesis. This mechanism has been underlined in cases of successful treatment with G-CSF alone after AML relapse post allogeneic bone marrow transplantation. 8 G-CSF can be useful in some selected cases of AML especially in elderly patients with hypoplastic AML who may not be likely candidates for chemotherapy. This treatment has many advantages. Response is rapidly obtained, side-effects are rare, outpatient care is made easier and quality of life improved. Prospective studies, especially in elderly patients, are required in order to understand in which circumstances G-CSF is efficient and how long the treatment should be administered. 1,2 The result of this translocation is the TEL-AML1 (ETV6-CBFA2) fusion gene detected only by FISH and/or by RT-PCR. The precise role of this event in leukemogenesis has not been completely elucidated thus far. According to Wiemels et al, 3 the TEL-AML1 gene fusion is shown to have originated in the prenatal period based on detecting TEL-AML1 fusion sequence in identical twins and in neonatal blood spot of children with ALL. 4 However, the latency between the birth and the onset of leukemia clearly demonstrates the need for important secondary and post-natal events in the promotion of ALL with TEL-AML1 fusion. Many secondary chromosomal changes
